243 related articles for article (PubMed ID: 28636655)
1. Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferon.
Mascia C; Vita S; Zuccalà P; Marocco R; Tieghi T; Savinelli S; Rossi R; Iannetta M; Pozzetto I; Furlan C; Mengoni F; Mastroianni CM; Vullo V; Lichtner M
PLoS One; 2017; 12(6):e0179400. PubMed ID: 28636655
[TBL] [Abstract][Full Text] [Related]
2. Active HCV infection is associated with increased circulating levels of interferon-gamma (IFN-γ)-inducible protein-10 (IP-10), soluble CD163 and inflammatory monocytes regardless of liver fibrosis and HIV coinfection.
Mascia C; Lichtner M; Zuccalà P; Vita S; Tieghi T; Marocco R; Savinelli S; Rossi R; Iannetta M; Campagna M; Schiavone F; Mengoni F; Russo G; Mastroianni CM; Vullo V
Clin Res Hepatol Gastroenterol; 2017 Dec; 41(6):644-655. PubMed ID: 28578937
[TBL] [Abstract][Full Text] [Related]
3. Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histology.
Lund Laursen T; Brøckner Siggard C; Kazankov K; Damgaard Sandahl T; Møller HJ; Ong A; Douglas MW; George J; Tarp B; Hagelskjaer Kristensen L; Lund Laursen A; Hiramatsu A; Nakahara T; Chayama K; Grønbaek H
Scand J Gastroenterol; 2018 Aug; 53(8):986-993. PubMed ID: 29987961
[TBL] [Abstract][Full Text] [Related]
4. During Hepatitis C Virus (HCV) Infection and HCV-HIV Coinfection, an Elevated Plasma Level of Autotaxin Is Associated With Lysophosphatidic Acid and Markers of Immune Activation That Normalize During Interferon-Free HCV Therapy.
Kostadinova L; Shive CL; Judge C; Zebrowski E; Compan A; Rife K; Hirsch A; Falck-Ytter Y; Schlatzer DM; Li X; Chance MR; Rodriguez B; Popkin DL; Anthony DD
J Infect Dis; 2016 Nov; 214(9):1438-1448. PubMed ID: 27540113
[TBL] [Abstract][Full Text] [Related]
5. Low levels of microbial translocation marker LBP are associated with sustained viral response after anti-HCV treatment in HIV-1/HCV co-infected patients.
Nyström J; Stenkvist J; Häggblom A; Weiland O; Nowak P
PLoS One; 2015; 10(3):e0118643. PubMed ID: 25785448
[TBL] [Abstract][Full Text] [Related]
6. IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV coinfection.
Reiberger T; Aberle JH; Kundi M; Kohrgruber N; Rieger A; Gangl A; Holzmann H; Peck-Radosavljevic M
Antivir Ther; 2008; 13(8):969-76. PubMed ID: 19195322
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal Assessment of Multiple Immunological and Inflammatory Parameters during Successful DAA Therapy in HCV Monoinfected and HIV/HCV Coinfected Subjects.
Zuccalà P; Latronico T; Marocco R; Savinelli S; Vita S; Mengoni F; Tieghi T; Borgo C; Kertusha B; Carraro A; D'Ettorre G; Vullo V; Mastroianni CM; Liuzzi GM; Lichtner M
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233234
[TBL] [Abstract][Full Text] [Related]
8. The dynamic relationship between innate immune biomarkers and interferon-based treatment effects and outcome in hepatitis C virus infection is altered by telaprevir.
Malone DF; Falconer K; Weiland O; Sandberg JK
PLoS One; 2014; 9(8):e105665. PubMed ID: 25166593
[TBL] [Abstract][Full Text] [Related]
9. Soluble CD163 and soluble CD14 plasma levels but not cellular HIV-DNA decrease during successful interferon-free anti-HCV therapy in HIV-1-HCV co-infected patients on effective combined anti-HIV treatment.
Parisi SG; Andreis S; Mengoli C; Menegotto N; Cavinato S; Scaggiante R; Andreoni M; Palù G; Basso M; Cattelan AM
Med Microbiol Immunol; 2018 Aug; 207(3-4):183-194. PubMed ID: 29523966
[TBL] [Abstract][Full Text] [Related]
10. Increased peripheral CD4
Langhans B; Nischalke HD; Krämer B; Hausen A; Dold L; van Heteren P; Hüneburg R; Nattermann J; Strassburg CP; Spengler U
J Hepatol; 2017 May; 66(5):888-896. PubMed ID: 28040549
[TBL] [Abstract][Full Text] [Related]
11. Dynamic Changes of Post-Translationally Modified Forms of CXCL10 and Soluble DPP4 in HCV Subjects Receiving Interferon-Free Therapy.
Meissner EG; Decalf J; Casrouge A; Masur H; Kottilil S; Albert ML; Duffy D
PLoS One; 2015; 10(7):e0133236. PubMed ID: 26181438
[TBL] [Abstract][Full Text] [Related]
12. Soluble Markers of Immune Activation Differentially Normalize and Selectively Associate with Improvement in AST, ALT, Albumin, and Transient Elastography During IFN-Free HCV Therapy.
Kostadinova L; Shive CL; Zebrowski E; Fuller B; Rife K; Hirsch A; Compan A; Moreland A; Falck-Ytter Y; Popkin DL; Anthony DD
Pathog Immun; 2018 Sep; 3(1):149-163. PubMed ID: 30370392
[TBL] [Abstract][Full Text] [Related]
13. Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection.
Romero AI; Lagging M; Westin J; Dhillon AP; Dustin LB; Pawlotsky JM; Neumann AU; Ferrari C; Missale G; Haagmans BL; Schalm SW; Zeuzem S; Negro F; Verheij-Hart E; Hellstrand K;
J Infect Dis; 2006 Oct; 194(7):895-903. PubMed ID: 16960776
[TBL] [Abstract][Full Text] [Related]
14. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM
Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511
[TBL] [Abstract][Full Text] [Related]
15. Elevated plasma soluble CD14 and skewed CD16+ monocyte distribution persist despite normalisation of soluble CD163 and CXCL10 by effective HIV therapy: a changing paradigm for routine HIV laboratory monitoring?
Castley A; Berry C; French M; Fernandez S; Krueger R; Nolan D
PLoS One; 2014; 9(12):e115226. PubMed ID: 25544986
[TBL] [Abstract][Full Text] [Related]
16. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.
Chayama K; Takahashi S; Toyota J; Karino Y; Ikeda K; Ishikawa H; Watanabe H; McPhee F; Hughes E; Kumada H
Hepatology; 2012 Mar; 55(3):742-8. PubMed ID: 21987462
[TBL] [Abstract][Full Text] [Related]
17. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.
Bernabucci V; Ciancio A; Petta S; Karampatou A; Turco L; Strona S; Critelli R; Todesca P; Cerami C; Sagnelli C; Rizzetto M; Cammà C; Villa E
World J Gastroenterol; 2014 Nov; 20(44):16726-33. PubMed ID: 25469044
[TBL] [Abstract][Full Text] [Related]
18. HIV Infection, HCV Coinfection, and Alcohol Use: Associations with Microbial Translocation and Immune Activation.
Monnig MA; Cohen R; Ramratnam B; McAdams M; Tashima K; Monti PM
Alcohol Clin Exp Res; 2019 Jun; 43(6):1126-1134. PubMed ID: 30908642
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of elevated serum interferon- inducible protein-10 levels in hepatitis C virus carriers with persistently normal serum transaminase levels.
Itoh Y; Morita A; Nishioji K; Narumi S; Toyama T; Daimon Y; Nakamura H; Kirishima T; Okanoue T
J Viral Hepat; 2001 Sep; 8(5):341-8. PubMed ID: 11555191
[TBL] [Abstract][Full Text] [Related]
20. Injecting drug use and hepatitis C virus infection independently increase biomarkers of inflammatory disease risk which are incompletely restored by curative direct-acting antiviral therapy.
Hearps AC; Vootukuru N; Ebrahimnezhaddarzi S; Harney BL; Boo I; Nguyen L; Pavlyshyn D; Dietze PM; Drummer HE; Thompson AJ; Jaworowski A; Hellard ME; Sacks-Davis R; Doyle JS
Front Immunol; 2024; 15():1352440. PubMed ID: 38420130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
